Clinical Trials Browser

Phase 3 × IDRX-42 × 90 days × Clear all

NCT07218926 2026-01-30

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

Phase 3 Recruiting

GastrointestinalSarcoma

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors